SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as investors highlight its position on the Base network and its backing by Coinbase Ventures, fueling community optimism about its role in the current 'privacy season.' Supporters are actively discussing the project's potential for significant growth, framing it as a key utility-driven asset for those prioritizing digital privacy and financial freedom.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay shares are experiencing significant volatility following a WSJ report that GameStop is building a stake in the company to potentially initiate a takeover bid. While the community is actively debating the feasibility of the mergerciting concerns over share dilution, massive debt requirements, and valuation disparitiesretail traders are driving heavy volume and speculation on potential options strategies as they react to the news.

Unleash Jugs

JUGS is gaining attention as a recently launched cryptocurrency, with community members actively discussing its speculative potential and viral branding.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano ($COCK) is trending as community members rally around its unique integration with real-world assets through Cocky Wings and passive income mechanics like liquid staking. Investors are actively discussing the project's long-term business potential and its ability to maintain high engagement across social platforms.

Centrifuge

Centrifuge is capturing investor interest as a leader in the Real World Assets sector, bolstered by the launch of tokenized financial products like the S&P 500 Index Fund Token. Community sentiment remains highly optimistic, with many focusing on the project's institutional-grade infrastructure and potential for long-term growth as tokenization becomes a core pillar of decentralized finance.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is currently in the spotlight following the announcement of a preliminary design for their Phase 3 trial of CAD-1005 to treat heparin-induced thrombocytopenia. While the community is actively debating the company's clinical prospects and high volatility, discussions are frequently dominated by concerns regarding the prevalence of automated bot activity on social platforms.

SkyAI is an all-in-one AI ecosystem powered by MCP, designed to seamlessly integrate intelligent solutions across industries.

SkyAI

SkyAI is drawing significant attention as traders compare its rapid momentum and bullish chart patterns to previous successful crypto runners. While some investors view the asset as a high-potential breakout candidate fueled by increasing accumulation, others remain cautious of pump-and-dump volatility within the speculative AI token sector.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is rallying significantly following a major earnings beat and a new business model centered on long-term data center contracts, which has prompted multiple analyst firms to aggressively hike price targets. The community is focused on the stock's transition from a cyclical chipmaker to a structural AI-infrastructure player, with heated debate surrounding the sustainability of its rapid valuation growth versus the bullish case fueled by NAND memory shortages and a massive share buyback program.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter's UPDOG token is gaining momentum as community members highlight its long-standing presence on the Solana network and its inclusion on the JUP strict list. Supporters are actively engaging in promotional campaigns and buy-bot activity to drive awareness around the project's longevity and unique joke-based brand.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token (VVV) is experiencing significant community attention driven by its role in decentralized, privacy-focused AI infrastructure and its recent integration of advanced models like DeepSeek. Traders are highlighting the project's deflationary burn mechanisms, reduced emission schedules, and the potential for a breakout as the broader AI sector heats up.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm

IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors...

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX ImmunityBio...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX INVESTOR ALERT: Pomerantz Law Firm...

INVESTOR REMINDER: Berger Montague Notifies ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Class Action Lawsuit and Deadline

INVESTOR REMINDER: Berger Montague Notifies ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Class Action Lawsuit and Deadline INVESTOR REMINDER: Berger Montague Notifies ImmunityBio, Inc. (NASDAQ...

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi...

IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt

IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt IBRX Lawsuit Alleges...

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman IBRX Lawsuit Alleges...

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit...

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Promoted Unapproved Drug Uses: Levi & Korsinsky

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Promoted Unapproved Drug Uses: Levi & Korsinsky IBRX...

<ul class="summary-bullets"><li>CEO Richard Adcock said the long-delayed Dunkirk manufacturing site is now “all systems go” after a unanimous resolution at a CCIDA board meeting.</li><li>The Dunkirk facility is expected to serve as a key U.S. production hub for Anktiva.</li><li>ImmunityBio has already invested over $100 million into the project.</li></ul>Shares of ImmunityBio, Inc. (IBRX) rose 1% in overnight trading on Wednesday after CEO Richard Adcock said that the company’s long-delayed Dunkirk manufacturing project is now “all systems go,” after local officials unanimously backed progress for the site supporting production of its cancer immunotherapy, Anktiva.&nbsp;<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> slid nearly 5% to end at $6.96 on Tuesday. However, shares rose 1% in extended trading.&nbsp;<h2 class="st-heading-2">Anktiva US Production Site Back On Track</h2>Following a unanimous consent resolution at a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/live/o1PfKhGG0YY">meeting</a> of the Chautauqua County Industrial Development Agency (CCIDA) on Tuesday, ImmunityBio said its long-delayed Dunkirk facility is now moving forward as a key U.S. manufacturing hub for Anktiva production.CEO Richard Adcock said that progress had previously stalled after parts of the buildout were left incomplete when a contractor entered bankruptcy, delaying installation and certification required to activate the site.“Unfortunately, the original contractor didn’t finish parts and other parts didn’t get done. They got trapped in that bankruptcy, and so we all got kind of stuck in limbo land,” Adcock said. “Now that all that’s in our rear view mirror, we can just focus going forward… it’s really now all systems go.”Adcock said that ImmunityBio has already invested over $100 million into the project and expects to deploy “tens to hundreds of millions” more as the facility moves towards operational readiness. The company has already begun hiring for the restart, identifying at least 19 roles spanning engineering, scientific, and quality-control functions. “These are going to be people with master’s and PhD-level positions… everything is being built out now that we’ve effectively been able to get ourselves untrapped in this situation,” he said.A key milestone now in focus is the installation of $50 million in high-speed fill-finish equipment, followed by regulatory certification before engineering runs and initial manufacturing operations can begin.“It’s not just us getting it ready and running it. It’s then also bringing in the FDA, bringing in the state, bringing in everybody else that regulates it to make sure they’ll certify it,” Adcock said.<h2 class="st-heading-2">Dunkirk Lease Deal Clears Path For Anktiva</h2>Momentum at the Dunkirk site also follows a revised lease agreement with New York State that replaces the earlier $1 lease arrangement under the former Athenex project, which ended after the company went bankrupt in 2023.&nbsp;In February, ImmunityBio completed its acquisition of the leasehold interest in the ISO Class 5 pharma manufacturing facility in Dunkirk from Athenex, which includes upstream and downstream processing, fill-finish capability and large-scale lyophilization capacity to produce Anktiva in the U.S.&nbsp;Under the revised lease terms, the company will pay $525,000 in annual rent, commit at least $40 million toward facility improvements and hire at least 100 employees by the end of 2028, with the workforce expected to expand to 450 by 2032.&nbsp;<h2 class="st-heading-2">The Anktiva Bull Case</h2>The Dunkirk manufacturing push comes as Anktiva continues to drive ImmunityBio’s revenue growth and international expansion strategy. “Since we started this project, we were approved with Anktiva in zero countries. As we sit here today, it’s approved in 34 countries and territories,” Adcock said.Preliminary net product revenue for Anktiva hit $44.2 million in the first quarter, up 168% from a year earlier, while full-year 2025 net product revenue rose to $113 million, up 700% from 2024.&nbsp;Anktiva recently secured conditional authorization across 27 European Union member states, plus Iceland, Liechtenstein and Norway, and also recently became commercially available in Saudi Arabia. The company is also pushing additional programs evaluating Anktiva across lung, pancreatic, colorectal and brain cancers, alongside studies in severe pneumonia, sepsis, long COVID and acute respiratory distress syndrome.<h2 class="st-heading-2">How Do Retail Traders Feel About IBRX?</h2>On Stocktwits, retail sentiment for IBRX has slipped to ‘bearish’&nbsp; from ‘bullish’ levels a week ago amid a 242% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_2acd0aa508.webp" alt="ibrx ss.png" width="969" height="139"><figcaption>TSLA sentiment and message volume as of April 29 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/BixbyKnolls/message/651636385">said</a>, “Major! Massive NEWS coming! Slingshot to new highs! Dunkirk and beyond!”<stembedurl>https://stocktwits.com/BixbyKnolls/message/651636385</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/BixbyKnolls/message/651631616">said</a>, “Ahead of plan on Dunkirk hiring! Unanimous approval to company plan and subsidies.&nbsp; BIg checks flowing out-&nbsp; Bigger money coming in soon.....”<stembedurl>https://stocktwits.com/BixbyKnolls/message/651631616</stembedurl>IBRX stock has jumped 165% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-lcid-sngx-srad-stocks-hit-52-week-lows-today/cZBq8xRRe33">LCID, SNGX, SRAD Stock Hit 52-Week Lows Today: What's Driving The Selloff?&nbsp;</a>

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push

The company ImmunityBio has already begun hiring to restart the Dunkirk facility, identifying at least 19 roles across multiple functions.

Equity

The company has already begun hiring to restart the Dunkirk facility, identifying at least 19 roles across multiple functions.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Continue higher

Sideways action

Retreat lower

What’s your read on the market for next week?

Stocktwits

Stocktwits Polls

Investors are bracing for key FDA milestones in May, specifically regarding sBLA classification and the upcoming earnings report.

With a high short interest and massive borrow ratios, bulls are closely tracking potential indicators of a short-covering event.

Discussion centers on the potential of NK-cell activation technology to redefine cancer care and replace outdated chemo treatments.

Massive investment in the Dunkirk facility and high-volume vial output suggest an anticipation of global commercial scale.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

IBRXImmunityBio Inc